SEER Inquiry System - Home
Welcome to the SEER Inquiry System (SINQ). SINQ is a collection of questions that cancer registrars have had while coding cancer cases. Click Search to look for specific questions or to select questions for a Report.
|Add to Report||ID||Question||Status||Last Updated|
|20130008||Primary site-Kidney: In which registry manual/section/page do you find information about how to correctly code the primary site in a patient with renal cell carcinoma in a transplanted kidney? I have been told it is C809 and C649. Please clarify.||Final||Mar 22 2013|
|20130007||MP/H Rules/Histology--Colon: Can we use rule H9 for a neuroendocrine tumor of the colon? What is the morphology code?
|Final||Feb 26 2013|
|20130006||MP/H Rules/Histology--Prostate: For a prostate case, where no pathology report is available but the MD does state the Gleason, is it ok to code the histology to Adenocarcinoma (8140)?||Final||Feb 26 2013|
|20130005||Reportability--Brain and CNS: I have a lot of spinal schwannoma & neurofibroma cases in the intradural space and I have made some reportable & others non-reportable. I would like to submit quality information but I am getting different answers. Could you please help me with this issue?||Final||Feb 21 2013|
|20130003||MP/H Rules--Head & Neck: Parotid gland MASC (Mammary Analogue Secretory Carcinoma). This histology is not listed in ICD-O-3. Should we code as 8550/3 or 8502/3? Our pathologist said "that MASC is a recently descibed salivary gland tumor type which as the name implies resembles secretory carcinoma of the breast."||Final||Jan 16 2013|
|20130002||Multiple Primaries--Heme & Lymphoid Neoplasms: This is a FOUR-PART question.
Based on the new Hematopoietic Rules, is the following scenario (see discussion) just ONE lymphoma case with follow-up for recurrences only? Or, do we abstract the transformation (2008) when the lymphoma recurs in 2010?
If the 2008 transformation is picked up as another primary, what is the accession year?
And to which primary would the 4/22/2010 recurrence apply?
|Final||Jan 16 2013|
|20130001||Reportability--Brain and CNS: Are any of these conditions reportable when they are found in the primary brain or CNS site?
9120/0 Hemangioma, NOS
9121/0 Cavernous hemangioma
9122/0 Venous hemangioma
|Final||Jan 16 2013|
|20120095||MP/H Rules/Multiple primaries--Breast: Regarding rule M6 in the breast MP/H rules, if a patient has a left breast inflammatory carcinoma (ductal with apocrine features on bx), and during work-up, an incidental 1.2 cm lobular carcinoma is discovered in the lateral right breast - localized without any skin involvement - does M6 still apply and this is considered a single primary? The managing physician seems to imply that these are 2 different primaries. However, rule M6 seems to state that inflammatory in either breast makes this a single primary.||Final||Jan 16 2013|
|20120094||Reportability: Given that per the 2012 SEER Manual and SINQ 20120081 VIN II-III is no longer reportable, does this also apply to AIN II-III, VAIN II-III, etc.? Or does this change only affect VIN II-III? See discussion.||Final||Jan 16 2013|
|20120093||MP/H Rules/Multiple primaries: How many primaries are to be abstracted and what rule applies when a patient has a serous carcinoma of the right ovary treated with neoadjuvant chemotherapy followed by a debulking surgery that also revealed a serous tubal intraepithelial carcinoma of the left fallopian tube? See discussion.||Final||Dec 14 2012|